Health Canada announces review of all MDMA trials, as complaint alleges major flaws and safety issues
Bethany Lindsay
CBC
April 8th, 2022
Read the full story here.
Bethany Lindsay
CBC
April 8th, 2022
Concerns about patient safety, reports of increased suicidal thinking, and allegations of flawed research are at the heart of a new complaint to Health Canada over the much-hyped clinical trials for the use of MDMA to treat post-traumatic stress disorder.
The complaint about Health Canada-approved trials conducted by the U.S.-based Multidisciplinary Association for Psychedelic Studies (MAPS) was submitted to the federal agency on March 4 by a group of academics and journalists.
Health Canada confirmed Wednesday that it's now reviewing all trials involving MDMA to ensure patient safety and compliance with regulations.
One of the signatories on the complaint is Emma Tumilty, a bioethicist at Deakin University in Australia. She said she was shocked by some of the things she's learned about the MAPS trials.
"I think there are other actors in this space trying to design studies to keep people safe and test whether this actually has an effect and look at it properly," she said.
Read the full story here.